COMMUNIQUÉS West-GlobeNewswire

argenx launches Phase II proof-of-concept clinical trial of ARGX-113 for the treatment of pemphigus vulgaris

26/09/2017 - 07:00

Interim data expected in H2 2018 September 26, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated [...]

ProLynx annonce l'octroi d'une subvention SBIR pour développer une nouvelle technologie pour les agonistes doubles de récepteurs

26/09/2017 - 00:27

SAN FRANCISCO, le 26 septembre 2017 (GLOBE NEWSWIRE) - ProLynx a annoncé aujourd'hui qu'elle s'est vue attribuer une subvention Small Business Innovation Research (SBIR) du NIH pour étendre sa plateforme technologique [...]

ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis

25/09/2017 - 22:00

Key updates QR-010 was observed to be safe and well-tolerated across all doses in this trial with no serious adverse events related to treatment. A clinically meaningful improvement of CF respiratory symptoms, as [...]

GENFIT : RESULTATS DU PREMIER SEMESTRE 2017 : TRESORERIE DE CLOTURE DE 126 M€ ET AVANCEES MAJEURES DANS LE DEVELOPPEMENT DU PORTEFEUILLE DE PRODUITS ET PROGRAMMES DE LA SOCIETE

25/09/2017 - 18:09

RESULTATS DU PREMIER SEMESTRE 2017 : TRESORERIE DE CLOTURE DE 126 M€ ET AVANCEES MAJEURES DANS LE DEVELOPPEMENT DU PORTEFEUILLE DE PRODUITS ET PROGRAMMES DE LA SOCIETE - Résultats semestriels traduisant la progression [...]

GENFIT: 2017 HALF-YEAR RESULTS: CASH POSITION AT END OF PERIOD AT €126M AND SIGNIFICANT ADVANCES IN THE COMPANY'S PIPELINE

25/09/2017 - 18:09

2017 HALF-YEAR Results: Cash position at end of period at €126M and significant advances in the Company's pipeline - Half year results reflect the progress of elafibranor Phase 3 RESOLVE-IT study in NASH - Launch of the [...]

Sanofi : Disclosure of trading in own shares

25/09/2017 - 18:00

Reporting EN This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, [...]

Sanofi : Déclaration des transactions sur actions propres

25/09/2017 - 18:00

Reporting FR This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, [...]

Ossur Hf : Transactions in relation to share buyback program

25/09/2017 - 18:00

Announcement from Össur hf. No. 69/2017 Reykjavík, 25 September 2017 On 15 August 2017, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2017. The purpose of the share buyback program is to [...]

Ossur Hf : Össur announces efficiency initiatives

25/09/2017 - 17:30

Announcement no. 68/2017 Reykjavík, 25 September 2017 Össur announces efficiency initiatives At the Capital Markets Day in Copenhagen on 27 September 2017, Össur's management will elaborate on growth, innovation, and [...]

Enzymatica AB: Notice of extraordinary general meeting regarding among other things personnel option program in Enzymatica AB (publ)

25/09/2017 - 17:00

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Press release Lund on September 25, 2017 Notice of [...]

ProLynx announces SBIR grant award to develop novel technology for dual receptor agonists

25/09/2017 - 15:00

SAN FRANCISCO, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Today, ProLynx announced it was awarded a Small Business Innovation Research (SBIR) grant from the NIH to expand its technology platform to control delivery of two or [...]

Novo Nordisk A/S - Share repurchase programme

25/09/2017 - 13:32

Bagsværd, Denmark, 25 September 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]

Summit Joins cTAP in Effort to Enhance Development of Utrophin Modulators and Other Treatments for DMD

25/09/2017 - 13:00

Summit Therapeutics plc ('Summit', or 'the Company') SUMMIT JOINS cTAP IN COLLABORATIVE EFFORT TO ENHANCE THE DEVELOPMENT OF UTROPHIN MODULATORS AND OTHER TREATMENTS FOR DUCHENNE MUSCULAR DYSTROPHY Oxford, UK, 25 [...]

argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis

25/09/2017 - 12:45

Non-regulated information September 25, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody- [...]

HomeVi announces the launch of syndication of EUR 1,020 million Senior Secured Term Loan B for debt refinancing

25/09/2017 - 08:30

Suresnes, September 25, 2017 - 8:30 am CET HomeVi S.A.S. ("HomeVi") today announced that it will shortly begin syndicating a Senior Secured Term Loan B of EUR 1,020 million and a Senior Secured Revolving Credit Facility [...]

Ambu A/S: Patient safety made simpler with innovative visualisation devices

25/09/2017 - 08:01

Integration of VivaSight further strengthens Ambu's aScope solution. In 2016, Ambu acquired Israeli company ETView and thereby the VivaSight products - single-use double-lumen and single-lumen tubes with integrated high [...]

Ambu A/S: Ambu launches 4th generation of single-use bronchoscopes

25/09/2017 - 07:59

Innovation: 'Ambu ® aScope TM 4 Broncho' unveiled today in Vienna at European intensive care congress. Improved image quality means that Ambu expects new scope to be relevant for 50% more hospital procedures. Over the [...]

Targovax granted US Patent for mutant-RAS neoantigen platform lead products

25/09/2017 - 07:00

Extends IP protection of TG01 and TG02 until 06.05.2034 Oslo, 25 September 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target [...]

IBA SA : IBA et Elekta signent un protocole d'entente portant sur le développement conjoint de software et de ventes pour soutenir le développement de la protonthérapie

23/09/2017 - 16:00

IBA et Elekta signent un protocole d'entente portant sur le développement conjoint de software et de ventes pour soutenir le développement de la protonthérapie SAN DIEGO, Etats-Unis, 23 septembre 2017 - IBA (Ion Beam [...]